Core Viewpoint - Freshpet's CEO, Billy Cyr, along with family members and trusts, plans to adopt trading plans to exercise options set to expire in 2026, while maintaining a significant ownership stake in the company [1][2][3]. Group 1: Trading Plans and Share Ownership - Billy Cyr and his family currently hold 1,322,737 shares, approximately 2.71% of Freshpet's outstanding shares [2]. - After executing the trading plan, Cyr and his family intend to retain at least 350,000 shares of Freshpet stock [2]. - The trading plan will comply with SEC rules and will not allow for share sales until after the fourth quarter financial results are reported in February 2026 [1]. Group 2: CEO's Perspective - Cyr has not sold any shares during his nine-year tenure as CEO and has acquired shares worth over $4 million at current prices [3]. - The decision to exercise options is driven by their impending expiration, not a lack of confidence in the company's future [3]. - Cyr emphasizes his belief in Freshpet as a strong investment that will enhance long-term shareholder value [3]. Group 3: Company Overview - Freshpet focuses on providing fresh, nutritious pet food made from locally sourced ingredients, prepared in small batches [4]. - The company's products are available through various retail channels across the U.S., Canada, and Europe, as well as online [5]. - Freshpet emphasizes integrity, transparency, and social responsibility in its operations [5].

Core Viewpoint - Freshpet's CEO, Billy Cyr, along with family members and trusts, plans to adopt trading plans to exercise options set to expire in 2026, while maintaining a significant ownership stake in the company [1][2][3] Company Actions - The trading plans will involve exercising options granted in 2016, which expire on September 6, 2026, and selling shares to cover exercise costs, taxes, and estate planning needs [1] - The stock trading plan will comply with Rule 10b5-1 of the Securities Exchange Act of 1934, with sales not occurring until after the fourth quarter financial results are reported in February 2026 [1] Ownership Details - Cyr and his family currently hold 1,322,737 shares, approximately 2.71% of Freshpet's outstanding shares, and plan to retain at least 350,000 shares post-exercise [2] - Cyr has not sold any shares during his nine-year tenure as CEO and has invested over $4 million in Freshpet shares at current prices [3] Company Mission and Products - Freshpet aims to enhance pet nutrition with fresh food made from locally sourced ingredients, prepared in small batches to preserve quality [4] - The company's products are available in various retail formats across the U.S., Canada, and Europe, emphasizing integrity and social responsibility in their operations [5]

Financial Performance - Net sales increased by 14.0% to $288.8 million in Q3 2025, up from $253.4 million in the prior year period, driven by volume gains of 12.9% and a favorable price/mix of 1.1%[4] - Gross profit for Q3 2025 was $114.2 million, representing 39.5% of net sales, a decrease from 40.4% in the prior year period, primarily due to reduced leverage on plant expenses[5] - Adjusted EBITDA for Q3 2025 was $54.6 million, compared to $43.5 million in the prior year period, reflecting increased Adjusted Gross Profit[8] - Net income for Q3 2025 was $101.7 million, significantly up from $11.9 million in the prior year, aided by a $77.9 million tax benefit due to sustained profitability[7] - For the first nine months of 2025, net sales rose by 14.6% to $816.8 million, compared to $712.5 million in the prior year period, driven by volume gains of 12.8%[8] - Adjusted Gross Profit for Q3 2025 was $132.8 million, or 46.0% of net sales, compared to 46.5% in the prior year period[5] - Net income attributable to common stockholders for Q3 2025 was $101.7 million, significantly higher than $11.9 million in Q3 2024[26] - Adjusted EBITDA for the nine months ended September 30, 2025 was $134,547,000, compared to $109,204,000 for the same period in 2024, reflecting a growth of 23.2%[33] - Adjusted EBITDA as a percentage of Net Sales improved to 18.9% in Q3 2025, up from 17.2% in Q3 2024[33] Expenses and Liabilities - SG&A expenses for Q3 2025 were $89.3 million, a decrease from $90.3 million in the prior year, with SG&A as a percentage of net sales decreasing by 480 basis points to 30.9%[5] - Adjusted SG&A expenses for Q3 2025 were $78.2 million, representing 27.1% of net sales, down from 29.3% in Q3 2024[30] - Total liabilities rose to $567.1 million as of September 30, 2025, up from $519.5 million at the end of 2024[24] - Interest expense net of interest income was $1,194,000 in Q3 2025, compared to a net income of $(40,000) in Q3 2024[33] - The company incurred $10,680,000 in distributor transition costs during the nine months ended September 30, 2025, due to a change in distribution partners[34] - The company reported a legal obligation expense of $716,000 in Q3 2025, with no corresponding expense in Q3 2024[34] Cash Flow and Assets - Cash and cash equivalents as of September 30, 2025, were $274.6 million, with outstanding debt of $396.8 million[10] - Cash and cash equivalents at the end of Q3 2025 were $274.6 million, slightly up from $268.6 million at the end of 2024[28] - The company reported net cash flows provided by operating activities of $105.5 million for the nine months ended September 30, 2025[28] - Total assets increased to $1.75 billion as of September 30, 2025, compared to $1.57 billion at the end of 2024[24] Guidance and Future Outlook - The company updated its 2025 guidance to reflect net sales growth of approximately 13%, down from a previous range of 13% to 16%[12] - The company expects to achieve positive free cash flow for fiscal year 2025, a year earlier than originally planned[3] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[31] - The company anticipates continued sales growth in the pet specialty channel despite the transition to a new distribution partner[34] Depreciation and Other Costs - Depreciation and amortization expenses increased to $23,650,000 in Q3 2025 from $18,709,000 in Q3 2024, representing a rise of 26.0%[33] - The loss on disposal of property, plant, and equipment was $126,000 in Q3 2025, down from $768,000 in Q3 2024[33] - Income tax benefit for Q3 2025 was $(77,958,000), compared to an expense of $54,000 in Q3 2024[33]

Net Sales Growth of 14% Outperforms CategoryCompany Achieves Positive Free Cash Flow in Third Quarter and Now Expects to be Free Cash Flow Positive in 2025Updates 2025 Guidance BEDMINSTER, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Freshpet, Inc. (“Freshpet” or the “Company”) (Nasdaq: FRPT) today reported financial results for its third quarter and nine months ended September 30, 2025. Third Quarter 2025 Financial Highlights Compared to Prior Year Period Net sales of $288.8 million, an increase of 14.0%.Gross ...

Core Viewpoint - Freshpet Inc. (NASDAQ:FRPT) shares are currently trading at $54.50, reflecting a slight increase of 0.70% in the current session, but the stock has seen a significant decline of 58.54% over the past year, raising questions about its valuation despite current performance [1]. Group 1: Stock Performance - Freshpet's stock has increased by 0.88% over the past month, but it has decreased by 58.54% in the past year [1]. - The current trading price of Freshpet shares is $54.50 [1]. Group 2: P/E Ratio Analysis - Freshpet has a P/E ratio of 82.0, which is significantly higher than the Food Products industry's aggregate P/E ratio of 17.71, suggesting that investors may expect better future performance from Freshpet compared to its peers [6]. - A higher P/E ratio may indicate that the stock is overvalued, although it could also reflect investor optimism about future performance and potential dividend increases [5][6]. Group 3: Investment Considerations - The P/E ratio is a useful metric for evaluating market performance, but it should be used cautiously as a low P/E can indicate undervaluation or weak growth prospects [9]. - Investors should consider the P/E ratio alongside other financial metrics, industry trends, and qualitative factors for a comprehensive analysis of a company's financial health [9].

Core Viewpoint - Freshpet (FRPT) is anticipated to report a year-over-year increase in earnings driven by higher revenues, with the actual results being a significant factor influencing its near-term stock price [1][2]. Financial Expectations - The upcoming earnings report is expected to reveal quarterly earnings of $0.43 per share, reflecting a year-over-year increase of +79.2% [3]. - Revenues are projected to reach $284.53 million, which is a 12.3% increase compared to the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 8.07% over the last 30 days, indicating a reassessment by analysts [4]. - Despite the downward revision, the Most Accurate Estimate for Freshpet is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +1.04% [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive Earnings ESP reading is a strong predictor of an earnings beat, particularly when combined with a favorable Zacks Rank [10]. - Freshpet currently holds a Zacks Rank of 5 (Strong Sell), complicating the prediction of an earnings beat despite the positive Earnings ESP [12][20]. Historical Performance - In the last reported quarter, Freshpet exceeded the expected earnings of $0.12 per share by delivering $0.33, resulting in a surprise of +175.00% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates two times [14]. Industry Comparison - Kraft Heinz (KHC), another player in the food industry, is expected to report earnings of $0.57 per share, indicating a year-over-year decline of -24% [18]. - Kraft Heinz's revenues are projected to be $6.25 billion, down 2.1% from the previous year, with a recent EPS estimate revision of 0.9% downward [19].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Freshpet, Inc. due to allegations of materially misleading business information issued by the company [1] Company Summary - Freshpet, Inc. (NASDAQ: FRPT) is facing scrutiny regarding its business practices, which may have misled investors [1] - Shareholders who purchased Freshpet securities may be entitled to compensation through a contingency fee arrangement, meaning no out-of-pocket fees or costs for them [1]

Core Viewpoint - Freshpet, Inc. is set to report its third-quarter results for the period ending September 30, 2025, on November 3, 2025, before the market opens [1] Group 1: Earnings Announcement - The company will host a conference call with its executive management team to discuss the third-quarter results, scheduled for 8:00 a.m. ET on November 3, 2025 [2] - The call will be accessible via a live broadcast on the company's website and will be archived for later access [3] Group 2: Company Overview - Freshpet's mission focuses on providing fresh food for pets, utilizing locally sourced ingredients and small-batch cooking methods to maintain quality [4] - The company's products are available through various retail channels across the U.S., Canada, and Europe, emphasizing integrity and social responsibility in its operations [5]

Core Viewpoint - Freshpet, Inc. is currently under investigation for potential securities fraud violations, which may impact its stock performance and investor confidence [1] Group 1 - The investigation is being conducted by the DJS Law Group, indicating potential legal implications for the company [1] - Investors are encouraged to discuss their rights in light of the ongoing investigation, suggesting that there may be significant concerns regarding the company's financial practices [1]

Core Viewpoint - Freshpet, Inc. is currently under a fraud investigation, and investors have the opportunity to join the legal proceedings with the Schall Law Firm [1] Group 1 - The investigation pertains to potential fraudulent activities involving Freshpet, Inc. [1] - Investors are being encouraged to participate in the investigation to seek potential remedies [1]